Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium

详细信息    查看全文

• 作者：Philip Sager ; MD ; FACC^a ; ⁿ ; ^o ; Jeffrey Heilbraun ; MS^b ; ⁿ ; ^o ; J. Rick Turner ; PhD^c ; ^o ; Gary Gintant ; PhD^d ; Mary J. Geiger ; MD ; PhD^e ; Peter R. Kowey ; MD^f ; ^g ; George A. Mansoor ; MD^h ; Boaz Mendzelevski ; MDⁱ ; Eric L. Michelson ; MD^j ; Norman Stockbridge ; MD ; PhD^k ; Michael A. Weber ; MD^l ; William B. White ; MD ; FASH ; FACP ; FAHA^m ; ^o ; ^{wwhite@nso1.uchc.edu}
• 刊名：American Heart Journal
• 出版年：2013
• 出版时间：April, 2013
• 年：2013
• 卷：165
• 期：4
• 页码：477-488
• 全文大小：281 K

文摘

This White Paper, prepared by members of the Cardiac Safety Research Consortium, discusses several important issues regarding the evaluation of blood pressure (BP) responses to drugs being developed for indications not of a direct cardiovascular (CV) nature. A wide range of drugs are associated with off-target BP increases, and both scientific attention and regulatory attention to this topic are increasing. The article provides a detailed summary of scientific discussions at a Cardiac Safety Research Consortium-sponsored Think Tank held on July 18, 2012, with the intention of moving toward consensus on how to most informatively collect and analyze BP data throughout clinical drug development to prospectively identify unacceptable CV risk and evaluate the benefit-risk relationship. The overall focus in on non-CV drugs, although many of the points also pertain to CV drugs. Brief consideration of how clinical assessment can be informed by nonclinical investigation is also outlined. These discussions present current thinking and suggestions for furthering our knowledge and understanding of off-target drug-induced BP increases and do not represent regulatory guidance.